Detlev joined the Boehringer Ingelheim Venture Fund as Investment Manager beginning of 2014. He serves as board member of ViraTherapeutics GmbH in Innsbruck (Austria), HepaRegenix GmbH in Tuebingen (Germany) and ImCheck Therapeutics SAS in Marseille (France).
Detlev studied chemistry in Braunschweig (Germany) and Bordeaux (France) and holds a PhD in cell and molecular biology. In 2001, he started his industrial career at metaGen Pharmaceuticals GmbH and Schering AG in Berlin (Germany) as a Scientist in Oncogenomics focusing on target validation and biomarker research.
In 2005, he joined Boehringer Ingelheim Pharma GmbH & Co.KG in Biberach an der Riss (Germany), where he held several positions: he started as laboratory head in Genomic research for new drug concept nominations. In 2009, he moved to Ridgefield, CT (USA) as project leader for an anti-inflammatory antibody project.
In 2011, Detlev returned to Biberach heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation.
Beginning of 2014, he joined the BIVF investing in clinical translation of pioneering therapeutic approaches, i.e. in the field of immuno-oncology, gene therapy and/or regenerative concepts.